421 related articles for article (PubMed ID: 35623169)
1. The role of neoantigens in tumor immunotherapy.
Shang S; Zhao Y; Qian K; Qin Y; Zhang X; Li T; Shan L; Wei M; Xi J; Tang B
Biomed Pharmacother; 2022 Jul; 151():113118. PubMed ID: 35623169
[TBL] [Abstract][Full Text] [Related]
2. Tumor neoantigens: Novel strategies for application of cancer immunotherapy.
Guan H; Wu Y; Li LU; Yang Y; Qiu S; Zhao Z; Chu X; He J; Chen Z; Zhang Y; Ding H; Pan J; Pan Y
Oncol Res; 2023; 31(4):437-448. PubMed ID: 37415744
[TBL] [Abstract][Full Text] [Related]
3. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
4. Research progress of neoantigens in gynecologic cancers.
Song Y; Zhang Y
Int Immunopharmacol; 2022 Nov; 112():109236. PubMed ID: 36113318
[TBL] [Abstract][Full Text] [Related]
5. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
6. Neoantigens in precision cancer immunotherapy: from identification to clinical applications.
Zhang Q; Jia Q; Zhang J; Zhu B
Chin Med J (Engl); 2022 Jun; 135(11):1285-1298. PubMed ID: 35838545
[TBL] [Abstract][Full Text] [Related]
7. Computational Prediction and Validation of Tumor-Associated Neoantigens.
Roudko V; Greenbaum B; Bhardwaj N
Front Immunol; 2020; 11():27. PubMed ID: 32117226
[TBL] [Abstract][Full Text] [Related]
8. Neoantigen: A New Breakthrough in Tumor Immunotherapy.
Zhang Z; Lu M; Qin Y; Gao W; Tao L; Su W; Zhong J
Front Immunol; 2021; 12():672356. PubMed ID: 33936118
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
Zheng Y; Fu Y; Wang PP; Ding ZY
Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
[TBL] [Abstract][Full Text] [Related]
10. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
[TBL] [Abstract][Full Text] [Related]
11. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
[TBL] [Abstract][Full Text] [Related]
12. Neoantigens and their clinical applications in human gastrointestinal cancers.
Eshkiki ZS; Agah S; Tabaeian SP; Sedaghat M; Dana F; Talebi A; Akbari A
World J Surg Oncol; 2022 Sep; 20(1):321. PubMed ID: 36171610
[TBL] [Abstract][Full Text] [Related]
13. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
[TBL] [Abstract][Full Text] [Related]
14. Development of neoantigens: from identification in cancer cells to application in cancer vaccines.
Ebrahimi N; Akbari M; Ghanaatian M; Roozbahani Moghaddam P; Adelian S; Borjian Boroujeni M; Yazdani E; Ahmadi A; Hamblin MR
Expert Rev Vaccines; 2022 Jul; 21(7):941-955. PubMed ID: 34196590
[TBL] [Abstract][Full Text] [Related]
15. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
16. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in personalized cancer immunotherapy with immune checkpoint inhibitors, T cells and vaccines.
Faghfuri E
Per Med; 2024 Jan; 21(1):45-57. PubMed ID: 38088165
[TBL] [Abstract][Full Text] [Related]
18. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.
Li J; Xiao Z; Wang D; Jia L; Nie S; Zeng X; Hu W
Mol Cancer; 2023 Aug; 22(1):141. PubMed ID: 37649123
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
Su S; Chen F; Xu M; Liu B; Wang L
Thorac Cancer; 2023 Dec; 14(34):3361-3368. PubMed ID: 37905603
[TBL] [Abstract][Full Text] [Related]
20. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]